Abstract CT236: A Two-Part Phase 2 Study of Itacitinib Immediate Release in Patients with Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy

Authors: Andrew T. Kuykendall, Lea Burke, Mani Lakshminarayanan, Philomena Colucci

Published: 2021-07-01

DOI: 10.1158/1538-7445.am2021-ct236

Source: Full article